Infect Chemother.  2016 Dec;48(4):324-329. 10.3947/ic.2016.48.4.324.

Acinetobacter Prosthetic Joint Infection Treated with Debridement and High-Dose Tigecycline

• Vila A
• Pagella H
• Amadio C
• Leiva A

• KMID: 2441327
• DOI: http://doi.org/10.3947/ic.2016.48.4.324

Abstract

Prosthesis retention is not recommended for multidrug-resistant Acinetobacter prosthetic joint infection due to its high failure rate. Nevertheless, replacing the prosthesis implies high morbidity and prolonged hospitalization. Although tigecycline is not approved for the treatment of prosthetic joint infection due to multidrug resistant Acinetobacter baumannii, its appropriate use may preclude prosthesis exchange. Since the area under the curve divided by the minimum inhibitory concentration is the best pharmacodynamic predictor of its efficacy, we used tigecycline at high dose, in order to optimize its efficacy and achieve implant retention in 3 patients who refused prosthesis exchange. All patients with prosthetic joint infections treated at our Institution are prospectively registered in a database. Three patients with early prosthetic joint infection of total hip arthroplasty due to multidrug resistant A. baumannii were treated with debridement, antibiotics and implant retention, using a high maintenance dose of tigecycline (100 mg every 12 hours). The cases were retrospectively reviewed. All patients signed informed consent for receiving off-label use of tigecycline. Tigecycline was well tolerated, allowing its administration at high maintenance dose for a median of 40 days (range 30-60). Two patients were then switched to minocycline at standard doses for a median of 3.3 months in order to complete treatment. Currently, none of the patients showed relapse. Increasing the dose of tigecycline could be considered as a means to better attain pharmacodynamic targets in patients with severe or difficult-to-treat infections. Tigecycline at high maintenance dose might be useful when retention of the implant is attempted for treatment for prosthetic joint infections due to multidrug resistant Acinetobacter. Although this approach might be promising, off-label use of tigecycline should be interpreted cautiously until prospective data are available. Tigecycline is probably under-dosed for the treatment of implant and biofilm associated infections.

Keyword

Prosthetic joint infection; Tigecycline; Acinetobacter; High dose

MeSH Terms

Acinetobacter baumannii
Acinetobacter*
Anti-Bacterial Agents
Arthroplasty, Replacement, Hip
Biofilms
Debridement*
Hospitalization
Humans
Informed Consent
Joints*
Microbial Sensitivity Tests
Minocycline
Off-Label Use
Prospective Studies
Prostheses and Implants
Prosthesis Retention
Recurrence
Retrospective Studies
Anti-Bacterial Agents
Minocycline

Reference

1. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR; Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis. 2013; 56:1–10.

2. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ. A two-stage retention debridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res. 2010; 468:2029–2038.

3. Jaén N, Martínez-Pastor JC, Muñoz-Mahamud E, García-Ramiro S, Bosch J, Mensa J, Soriano A. Long-term outcome of acute prosthetic joint infections due to gram-negative bacilli treated with retention of prosthesis. Rev Esp Quimioter. 2012; 25:194–198.

4. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012; 54:1699–1709.

5. MacGowan AP Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008; 62:Suppl 1. i11–6.

6. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006; 58:1221–1229.

7. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014; 18:R90.

8. Bengtsson S, Bjelkenbrant C, Kahlmeter G. Validation of EUCAST zone diameter breakpoints against reference broth microdilution. Clin Microbiol Infect. 2014; 20:O353–60.

9. Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015; 59:1650–1655.

10. Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis. 2008; 14:512–514.

11. Humphries RM, Kelesidis T, Dien Bard J, Ward KW, Bhattacharya D, Lewinski MA. Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J Med Microbiol. 2010; 59:1383–1386.

12. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol. 2009; 47:1613.

13. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013; 57:1756–1762.

14. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014; 44:1–7.

15. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and treatment. Swiss Med Wkly. 2005; 135:243–251.

16. Jones RN. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn Microbiol Infect Dis. 1999; 35:249–252.

17. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007; 45:227–230.

18. Beieler AM, Belknap RW, Dayton MR, Price CS, Morgan SJ. Eradication of multidrug-resistant Acinetobacter baumannii in a female patient with total hip arthroplasty, with debridement and retention: a case report. J Med Case Reports. 2009; 3:45.

19. Xie J, Wang T, Sun J, Chen S, Cai J, Zhang W, Dong H, Hu S, Zhang D, Wang X, Dong Y. Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Int J Infect Dis. 2014; 18:62–67.

20. Karani O, Charkoftaki G, Vryonis E, Skoutelis A, Markantonis S, Archontaki H, Dokoumetzidis A, Valsami G. Assessment of dosage regimens of tigecycline in hospitalised patients. In : Abstracts of the Annual Meeting of the Population Approach Group in Europe; 2011. 20:p. Abstr 2165.